Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia.

Authors

Mohamed Aseafan, Faisal Azam, Ahmed S Alanazi, Shaheed Alhumaid, Nawaf H Almalki, Mohamed Masoud, Zainab Alsharef, Hany Soliman, Mohamed El-Khedr Hassan

Published in

Journal of medical economics. Volume 29. Issue 1. Pages 2063-2075. Epub Jul 31, 2026.

Abstract

The budget impact of introducing dostarlimab plus carboplatin-paclitaxel (CP) as a first-line treatment option for primary advanced or recurrent endometrial cancer (EC) in Saudi Arabia was evaluated from the perspective of the Saudi national payer.
The budget impact model (BIM) utilized epidemiological, clinical, and cost and resource use inputs to evaluate the total costs associated with a market scenario without dostarlimab versus a market scenario with dostarlimab over a three-year time horizon (2026-2028). Currently available comparator treatments in Saudi Arabia were evaluated based on associated market share and relevance as comparable treatment regimens to dostarlimab plus CP. A one-way sensitivity analysis was performed to identify the sensitivity of the BIM to changes in input parameters.
Out of 250 eligible patients, 58 were estimated to receive dostarlimab plus CP as a first-line EC treatment during its first year on the market, increasing to 242 out of 569 eligible patients in the third year. The resulting annual budget impact was -$326,607 in the first year and -$668,830 in the third year of market availability, with a total cumulative budget impact of -$1,650,171 over the three-year time horizon. The mean annual budget impact per patient treated with dostarlimab plus CP was -$4,388.57, a decrease of -1.84% compared with the scenario without dostarlimab.
The introduction of dostarlimab plus CP to healthcare settings for first-line treatment of primary advanced and recurrent EC was found to be budget neutral in this model, with lower treatment acquisition costs and decreased second-line subsequent treatment costs compared with the other currently available treatment options.

PMID:
42535775
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.